Mapping Key Clinical Trial Eligibility Criteria (EC) to Real-world Data (RWD): An Example Using KENYOTE-48

Extrapolating Randomized Clinical Trials (RCTs) evidence to the overall population is methodologically challenging. Here, we applied a novel methodology to map key EC from KEYNOTE-48 to patients initiating 1L pembrolizumab using RWD. Instead of filtering real-world patients based on EC which can rapidly shrink the sample size, we propose creating an augmented population to improve the power of RWD analyses.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: 155 Source Type: research